Publication date: Jan 12, 2021
Imatinib, a cancer treatment, stopped an injury response mechanism of the central nervous system (CNS) from activating, damage to which is a hallmark of multiple sclerosis (MS), an early study reported.
Treatment with imatinib lessened immune cell infiltration and eased disease progression in mouse models of MS. Study researchers suggested that treatments with a similar mechanism of action might be of benefit in neurological diseases marked by BBB disruption.
In a previous study in a rat EAE model, the researchers showed that treatment with imatinib, approved to treat certain types of leukemia (a cancer that begins in white blood cells) and other cancers, preserved BBB integrity and ameliorated clinical symptoms of the disease.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Cancer |
| drug | DRUGBANK | Imatinib |
| disease | MESH | multiple sclerosis |
| disease | MESH | disease progression |
| disease | MESH | experimental autoimmune encephalomyelitis |
| disease | MESH | leukemia |